Highest U.S. Honor for Technological Innovation Awarded to Genzyme

Genzyme Receives President's National Medal of Technology

30-Jul-2007

Genzyme Canada, the Canadian affiliate of Genzyme Corp., announced that the Company has been awarded the 2007 US National Medal of Technology, the highest honor for technological innovation. The Medal recognizes Genzyme Corp. for "pioneering a business that has led to dramatic improvements in the health of thousands of patients with rare diseases and harnessing the promise of biotechnology to develop innovative new therapies."

"This is a tremendous honor to receive such a prestigious award," said Brian Lewis, General Manager, Genzyme Canada. "This award recognizes Genzyme's extraordinary contributions to the biotechnology industry and the years of innovation leadership. It is also a mark of respect for Genzyme researchers who work tirelessly to improve the lives of people affected by rare diseases and strive to meet the significant unmet medical needs of people in Canada and around the globe."

Since being established in 1981, Genzyme has pioneered the development of the first-ever treatments for four rare diseases - Cerezyme for Gaucher disease; Fabrazyme for Fabry disease; Aldurazyme (developed with partner BioMarin Pharmaceutical) for MPS I disease; and Myozyme for Pompe disease. All treatments are available in Canada and are currently being used to treat Canadians affected with these devastating conditions.

The National Medal of Technology award recognizes those who have made lasting contributions to competitiveness, standard of living and quality-of-life through technological innovation, and those who have made substantial contributions to strengthening the technological workforce. The Medal also seeks to inspire future generations to prepare for and pursue technical careers.

https://www.bionity.com/en/news/66656/highest-u-s-honor-for-technological-innovation-awarded-to-genzyme.html